IP Library Granted Patent US 9,938,285
Granted Patent B2
US 9,938,285 · App. 15/110,824 · Granted Apr 10, 2018

Process for improved oxymorphone synthesis

Inventors: Joshua Robert Giguere (Coventry, RI); Keith Edward McCarthy (Coventry, RI); Marcel Schleusner (Groningen, NL)
Assignee: RHODES TECHNOLOGIES
C07D489/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,938,285
App. No.
15/110,824
Granted
Apr 10, 2018
Kind
B2
Abstract

Processes for preparing oxymorphone are provided. Said processes encompass a step which is a hydrogenation of an 14-hydroxymorphinone salt in the presence of trifluoroacetic acid and/or a glycol.

Claims (20)

1. A process for preparing oxymorphone or a salt or solvate thereof from a 14-hydroxymorphinone salt or a solvate thereof

the process comprising the steps of

(a) providing a solution or suspension of the 14-hydroxymorphinone salt or a solvate thereof;

(b) adding trifluoroacetic acid and/or a glycol; and

(c) reducing the 14-hydroxymorphinone present in the solution or suspension to the oxymorphone by hydrogenation,

wherein

X n− is an anion selected from the group consisting of Cl − , HSO 4 − , SO 4 2− , methanesulfonate, tosylate, trifluoroacetate, H 2 PO 4 − , HPO 4 2− , PO 4 3− , oxalate, perchlorate, and any mixtures thereof; and

n is 1,2, or 3.

2. The process of claim 1 , wherein trifluoroacetic acid and the glycol are added in step (b).

3. The process of claim 1 , wherein n is 2 and X n− is SO 4 2− .

4. The process of claim 1 , wherein the amount of trifluoroacetic acid is 99 mol % or less as compared to the molar amount of 14-hydroxymorphinone contained in the 14-hydroxymorphinone salt.

5. The process of claim 4 , wherein the amount of trifluoroacetic acid is from 30 mol % to 50 mol % as compared to the molar amount of 14-hydroxymorphinone contained in the 14-hydroxymorphinone salt.

6. The process of claim 1 , wherein the glycol is selected from the group consisting of ethylene glycol, propylene glycol, 1,3-propanediol, 1,2-butanediol, 1,3-butanediol, neopentylglycol, and mixtures thereof.

7. The process of claim 6 , wherein the glycol is ethylene glycol, propylene glycol, or a mixture thereof.

8. The process of claim 1 , wherein the glycol added in step (b) is in the range of from 1 to 8 volumes/weight calculated from the glycol volume in mL in relation to the weight in grams of the 14-hydroxymorphinone salt.

9. The process of claim 1 , wherein the hydrogenation in step (c) is performed with H 2 and a hydrogenation catalyst.

10. The process of claim 1 , wherein a mixture of water and the glycol is used as solvent, wherein the mixture is in a range from 20:80 to 45:55 glycol:water.

11. The process of claim 1 , additionally comprising the step:

(d) adding a base, thus raising the pH to a pH where the oxymorphone precipitates as its free base, and isolating the oxymorphone as its free base or a solvate thereof.

12. The process of claim 11 , wherein the base added in step (d) is NaOH.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2026
From: RHODES TECHNOLOGIES
To: KNOA PHARMA LLC
Reel/Frame 075838/0956 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2017
From: GIGUERE, JOSHUA R.; MCCARTHY, KEITH E.; SCHLEUSNER, MARCEL
To: RHODES TECHNOLOGIES
Reel/Frame 043345/0564 →
Continuity (3)
Provisional Application 61927938 · Jan 15, 2014
Related Publication 20170022209A1 · Jan 26, 2017
Related Publication 20170253604A9 · Sep 7, 2017